The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Improving tumor characterization and treatment precision with the new definition of HRMM
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, briefly discusses the upcoming revisions to the criteria for high-risk multiple myeloma (HRMM) by the International Myeloma Working Group (IMWG). Whole genome sequencing (WGS) must now be performed to provide a more comprehensive risk assessment, allowing for improved tumor characterization and treatment precision. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
